

---

## CURRICULUM VITAE

October 2017

---

NAME Andreas KRONBICHLER Medical University of Innsbruck Internal Medicine IV (Nephrology and Hypertension) Anichstraße 35 6020 Innsbruck (Austria)			
EDUCATION/TRAINING ( <i>Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.</i> )			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Medical University Innsbruck	M.D.	2010	Medicine
Medical University Innsbruck	PhD	2017	Cardiovascular Medicine

### **PROFESSIONAL EXPERIENCE**

#### Positions and employments

2010-2011	Internship and Residency, Departments of Medicine (various), University of Jena, Germany
2011-2014	Internship and Residency, Departments of Medicine (various), Medical University Innsbruck, Austria
2014-2015	Clinical Fellowship, Honorary Research Fellow, Addenbrooke's Hospital, Vasculitis and Lupus Clinic, University of Cambridge, United Kingdom
2015-2017	Departments of Medicine (various), Medical University Innsbruck, Austria
2017-ongoing	Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Austria

#### Other professional experiences

2015-2016	Guest Editor BioMed Research International ('Focal Segmental Glomerulosclerosis: Genetics, Mechanism, and Therapies')
2016-2017	Guest Editor BioMed Research International ('Nephrotic Syndrome: Genetics, Mechanism, and Therapies')

### **SCIENTIFIC SOCIETIES**

Member of the "European Vasculitis Study Group (EUVAS)"  
Member of the "Lupus Nephritis Trial Network (LNTN)"  
Member of the "European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA)"  
Member of the "Immunonephrology Working Group (IWG, ERA-EDTA)"  
Member of the "Austrian Society of Nephrology (ÖGN)"  
Member of the "Austrian Society of Rheumatology (ÖGR)"  
Member of the "Austrian Society of Internal Medicine (ÖGIM)"  
Member of the "Austrian Apheresis Association (AAA)"

## **SELECTED PUBLICATIONS (from year 2009 onwards)**

1. Schramek H, Sarközi R, Lauterberg C, **Kronbichler A**, Pirklbauer M, Albrecht R, Noppert SJ, Perco P, Rudnicki M, Strutz FM, Mayer G. Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells. *Lab Invest* 2009; 89:1304-16.
2. Sarközi R, Hauser C, Noppert SJ, **Kronbichler A**, Pirklbauer M, Haller VM, Grillari J, Grillari-Voglauer R, Mayer G, Schramek H. Oncostatin M is a novel inhibitor of TGF- $\beta$  1-induced matricellular protein expression. *Am J Physiol Renal Physiol* 2011; 301:F1014-25.
3. **Kronbichler A**, Mayer G. Renal involvement in autoimmune connective tissue diseases. *BMC Medicine* 2013, 11:95.
4. **Kronbichler A**, König P, Busch M, Wolf G, Mayer G, Rudnicki M. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases. *Wien Klin Wochenschr* 2013; 125:328-33.
5. Neuwirt H, **Kronbichler A**. Dabigatran pharmacokinetics-implications for treatment. *Am J Kidney Dis* 2013; 62:180.
6. Welzl K, Weinberger B, **Kronbichler A**, Sturm, G, Kern G, Mayer G, Grubeck-Loebenstien B, Koppelstaetter C. How immunosuppressive therapy affects T cells from kidney transplanted patients of different age: the role of latent CMV infection. *Clin Exp Immunol* 2014; 176:112-9.
7. **Kronbichler A**, Kerschbaum J, Rudnicki M. Induction regimens for ANCA-Associated Vasculitis. *N Engl J Med* 2013; 369:1864.
8. **Kronbichler A**, Oelzner P, Syrbe G, Lopatta E, Wolf G, Neumann T. Bilateral pulmonary embolism in twins with PAI-1 4G/5G gene polymorphism: a case report. *Wien Klin Wochenschr* 2014; 126:53-5.
9. **Kronbichler A**, Mayer G. Nephrotic syndrome; is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis? *J Nephropathol* 2014; 3:1-3.
10. **Kronbichler A**, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, Bruchfeld A, Mayer G, Rudnicki M. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: A systematic review. *Am J Nephrol* 2014; 39:322-330.
11. **Kronbichler A**. Boon and bane of remission induction with rituximab in ANCA-associated vasculitis: lessons learned from the RAVE-ITN follow-up study. *J Renal Inj Prev* 2013; 3:9-10.
12. **Kronbichler A**, Bruchfeld A. Rituximab in Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis. *Nephron Clin Pract* 2014;128(3-4):277-82.
13. **Kronbichler A**, Frank R, Kirschfink M, Szilagyí A, Csuka D, Prohaszka Z, Schratzberger P, Lhotta K, Mayer G. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. *Medicine* 2014; 93:e143.
14. **Kronbichler A**, Jayne DR. Con: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab? *Nephrol Dial Transplant* 2015; 30:1075-81.
15. **Kronbichler A**, Jayne DR. Opponent's comments. *Nephrol Dial Transplant* 2015; 30:1087-8.
16. **Kronbichler A**, Jayne DRW, Mayer G. Frequency, Risk Factors and Prophylaxis of Infection in ANCA-Associated Vasculitis. *Eur J Clin Invest* 2015;45(3):346-68.
17. Shin JI, **Kronbichler A**. Rituximab for patients with nephrotic syndrome. *Lancet* 2015; 385:225-6.
18. **Kronbichler A**, Kerschbaum J, Mayer G. The Influence and Role of Microbial Factors in Autoimmune Kidney Diseases: A Systematic Review. *J Immunol Res.* 2015; 2015:858027.
19. **Kronbichler A**, Gut N, Zwerina J, Neuwirt H, Rudnicki M, Mayer G. Extending the spectrum of a chameleon: IgG4-related disease appearing as interstitial nephritis and mimicking anti-neutrophil cytoplasmic antibody-associated vasculitis. *Rheumatology* 2015; 54:1936-8.
20. **Kronbichler A**, Brezina B, Quintana LF, Jayne DRW. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. *Autoimmun Rev* 2016; 15(1):38-49.
21. **Kronbichler A**, Gründlinger G, Kerschbaum J, Leierer J, Mayer G, Rudnicki M. Evaluation and Validation of Biomarkers in ANCA-Associated Vasculitis. *Nephrol Dial Transplant* 2016, 31:930-6.
22. Rudnicki M, Perco P, D'haene B, Leierer J, Heinzl A, Mühlberger I, Sunzenauer J, Regele H, **Kronbichler A**, Mestdagh P, Vandesompele J, Mayer B, Mayer G. An integrative analysis of renal

- miRNA- and mRNA-expression signatures in progressive chronic kidney disease. *Eur J Clin Invest* 2016; 46:213-26.
23. **Kronbichler A**, Leierer J, Oh J, Meijers B, Shin JI. Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis. *Biomed Res Int* 2016;2016:2150451.
  24. Beer A, Mayer G, **Kronbichler A**. Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades. *Biomed Res Int* 2016;2016:4192578.
  25. Kim SH, Park SJ, Han KH, **Kronbichler A**, Saleem MA, Oh J, Lim BJ, Shin JI. Pathogenesis of minimal change nephrotic syndrome: an immunological concept. *Korean J Pediatr* 2016; 59:205-11.
  26. **Kronbichler A**. Herzinfarkt nach Rituximab: Zusammenhang nicht ausgeschlossen. *Dtsch Med Wochenschr* 2016; 141:846.
  27. **Kronbichler A**, Oh J, Meijers B, Shin JI. Focal Segmental Glomerulosclerosis: Genetics, Mechanism, and Therapies. *Biomed Res Int* 2016; 2016:9643785.
  28. **Kronbichler A**, Saleem MA, Meijers B, Shin JI. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View. *J Immunol Res* 2016; 2016:2068691.
  29. **Kronbichler A**, Neumann I, Mayer G. Moderator's view: the use of calcineurin inhibitors in the treatment of lupus nephritis. *Nephrol Dial Transplant* 2016; 31:1572-6.
  30. Leierer J, Mayer G, **Kronbichler A**. Primary Focal Segmental Glomerulosclerosis: miRNAs and Targeted Therapies. *Eur J Clin Invest* 2016; 46:954-964.
  31. **Kronbichler A**, Shin JI. Letter to the Editor: "Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis". *Clin Rheumatol*. 2016; 35:2867-2868.
  32. **Kronbichler A**, Leierer J, Leierer G, Mayer G, Casian A, Höglund P, Westman K, Jayne DRW. Clinical Associations with Venous Thromboembolism in ANCA-Associated Vasculitides. *Rheumatology* 2017; 56:704-708.
  33. Van Daalen EE, Rizzo R, **Kronbichler A**, Wolterbeek R, Bruijn JA, Jayne DR, Bajema IM, Rahmatulla C. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. *Ann Rheum Dis* 2017; 76:1064-1069.
  34. Lee JW, Kim SH, Park SJ, Lee KH, Park JH, **Kronbichler A**, Eisenhut M, Kim JH, Lee JW, Shin JI. The value of delta neutrophil index in young infants with febrile urinary tract infection. *Sci Rep* 2017; 7:41265.
  35. Reinstadler SJ, **Kronbichler A**, Reindl M, Feistritzer HJ, Innerhofer V, Mayr A, Klug G, Tiefenthaler M, Mayer G, Metzler B. Acute kidney injury is associated with microvascular myocardial damage following myocardial infarction. *Kidney Int* 2017; 92:743-750.
  36. **Kronbichler A**, Windpessl M, Pieringer H, Jayne DRW. Rituximab for immunologic renal disease: What the nephrologist needs to know. *Autoimmun Rev* 2017; 16:633-643.
  37. Park JH, Byeon HJ, Lee KH, Lee JW, **Kronbichler A**, Eisenhut M, Shin JI. Delta neutrophil index (DNI) as a novel diagnostic and prognostic marker of infection: a systematic review and meta-analysis. *Inflamm Res*. 2017 Jun 23. doi: 10.1007/s00011-017-1066-y.
  38. Danlos FX, Rossi GM, Blockmans D, Emmi G, **Kronbichler A**, Durupt S, Maynard C, Luca L, Garrouste C, Lioger B, Mourot-Cottet R, Dhote R, Arlet JB, Hanslik T, Rouvier P, Ebbo M, Puéchal X, Nochy D, Carlotti A, Mouthon L, Guillevin L, Vaglio A, Terrier B. Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome. *Autoimmun Rev*. 2017 Aug 2. pii: S1568-9972(17)30203-3. doi: 10.1016/j.autrev.2017.07.020.
  39. **Kronbichler A**, Oh J, Meijers B, Mayer G, Shin JI. Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy. *BioMed Res Int* 2017; 2017:1936372.
  40. Lee KH, **Kronbichler A**, Park DDY, Park YM, Moon H, Kim H, Choi J, Choi YS, Shim S, Lyu IS, BH, Han Y, Lee D, Lee S, Yoo BH, Lee KH, Kim TL, Kim H, Shim JS, Nam W, So H, Choi SY, Lee S, Shin JI. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. *Autoimmun Rev*, accepted.
  41. Lee KH, Park JH, Kim DH, Hwang J, Lee G, Hyun JS, Heo ST, Choi JH, Kim M, Kim M, Kim SI, Eisenhut M, **Kronbichler A**, Shin JI. Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP). *Med Hypotheses* 2017; 108:42-45.

42. Eo TS, Chun KJ, Hong SJ, Kim JY, Lee IR, Lee KH, Eisenhut M, **Kronbichler A**, Shin JI. Clinical Presentation, Management, and Prognostic Factor of Idiopathic Systemic Capillary Leak Syndrome: A Systematic Review. *J Allergy Clin Immunol Pract*, accepted.
43. **Kronbichler A**. Therapeutic Plasma Exchange Strategy in Complement-mediated Diseases. An Overview. *Ther Apher Dial*, accepted.
44. **Kronbichler A**. Biological Agents and Therapeutic Plasma Exchange – Can They Coexist in the Future? *Ther Apher Dial*, accepted.
45. Park JH, Lee GH, Lee SM, **Kronbichler A**, Shin JI. Posterior Nutcracker Syndrome: A Systematic Review of the Literature. *Vasa*, accepted.
46. Lee KS, **Kronbichler A**, Eisenhut M, Lee KH, Shin JI. Cardiovascular Involvement in Systemic Rheumatic Diseases: Practical View for Rheumatologists and Cardiologists. *Autoimmun Rev*, accepted.
47. Park JH, Kim JH, Jo KE, Na SW, Eisenhut M, Kronbichler A, Lee KH, Shin JI. Field Synopsis and Re-analysis of Systematic Meta-analyses of Genetic Association Studies in Multiple Sclerosis: a Bayesian Approach. *Mol Neurobiol*, accepted.
48. Nakagomi D, **Kronbichler A**, Witte T, Mohammad AJ, Jayne D. Efficacy of rituximab in refractory and relapsing Takayasu arteritis: a case series. *Rheumatology*, accepted.

### **AWARDS**

ERA-EDTA Long-Term Fellowship (LTF) 08/2014 – 07/2015  
 Poster Prize Austrian Society Nephrology 2015  
 Hans-Krister Stummvoll Award 2017

### **RESEARCH GRANTS**

NIHR BRC Immunity, Infection and Inflammation (Main Applicant, £14,000, 03/2015-08/2015), 'Composition of the human microbiome in granulomatosis with polyangiitis: A pilot study'  
 Addenbrooke's Charitable Trust (Co-Applicant, £18,937, 07/2015-06/2016), 'Quantitative proteomics by SWATH MS identifies the role of complement, cytokines and chemokines in the pathogenesis of PR3-ANCA positive vasculitis'  
 Arthritis Research UK (Co-Applicant, £290,430,64, 01/2016-01/2018), 'The significance of *Staphylococcus aureus* carriage and granulomatosis with polyangiitis: Pathophysiological alterations unraveled'  
 ÖGR Wissenschaftspreis Pfizer (Main Applicant €10,000) 12/2016  
 TWF 2016 (Co-Applicant, Acute kidney injury in reperfused ST-Elevation myocardial infarction, €36,000) 12/2016

Innsbruck, 30<sup>th</sup> October 2017



Signature: Andreas Kronbichler, M.D., PhD